Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Eichhorst, Barbara  [Clear All Filters]
2024
Cramer P, von Tresckow J, Fink A-M, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol. 2024.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AMaria, Fürstenau M, Kater A, van der Spek E, et al. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. Am J Hematol. 2024.
2023
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(19):1739-1754.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink A-M, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2023.
von Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, et al. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group. Ann Hematol. 2023.
2021
Fürstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dörfel S, Aldaoud A, von Tresckow J, et al. Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am J Hematol. 2021.
2020
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, et al. Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol. 2020.